Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib added to 10-day decitabine in unfit AML and high-risk MDS patients aged ≥66 years
2015-002855-85Phase 2Completed
- Sponsor
- HOVON
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Decitabine 10-day regimen with Ibrutinib plus decitabine 10-day regimen (2 arms). Primary endpoint: Cumulative CR/CRi rate after 3 cycles. Started Nov 2015; status: completed.
02
Drugs
ibrutinibdecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-002855-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002855-85.